Lung cancer continues to be on the cutting edge of targeted therapies. The range of actionable targets has expanded from EGFR mutations to now encompass alterations in ALK, ROS1, BRAF, and more. In patients with lung cancer and known oncogenic drivers, we can substantially improve survival by leveraging targeted therapies, thereby making biomarker testing in these patients of critical importance. 2 key biomarkers poised to enter the clinic in 2020, RET and MET exon 14 (METex14), and revisit 2 biomarkers already in practice, NTRK and ROS1.

Immune checkpoint inhibitors have revolutionized the management of lung cancer with each passing day, new indications are emerging. We propose to have a virtual meeting on Oncology Update: Treatment Paradigm in the management of Lung Cancer 2021 & Beyond on 23^rd & 24^th April 2021 between 6pm to 9.30pm. The Conference is organized under the aegis of Update in Oncology X. We expect an august Gathering of more than 250+ Participants Pan India including students from the Teaching institute during live interaction

Warm Personal Regards

Dr. Shyam Agarwal
Chairman & Director
Dept. of Oncology
Sir Gangaram Hospital
New Delhi